Previous Close | 12.68 |
Open | 12.57 |
Bid | 12.56 x 800 |
Ask | 12.57 x 1400 |
Day's Range | 12.35 - 12.77 |
52 Week Range | 11.30 - 19.77 |
Volume | |
Avg. Volume | 849,925 |
Market Cap | 1.373B |
Beta (5Y Monthly) | 0.93 |
PE Ratio (TTM) | 14.96 |
EPS (TTM) | 0.84 |
Earnings Date | Sep 21, 2023 - Oct 05, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Oct 07, 2008 |
1y Target Est | 17.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for MDRX
CHICAGO, September 18, 2023--Veradigm Inc. (Nasdaq: MDRX) announced today that the work effort to conclude on its previously disclosed accounting and internal control errors has taken longer than previously expected, and more time is needed to complete its audit procedures. As such, today the Company will not be filing its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K"), or its Quarterly Reports on Forms 10-Q for the quarters ended March 31, 2023, and June 30, 2
Federal guidelines embrace importance of patient addresses for health IT developers powering analytics, patient matching, and overall careRANCHO SANTA MARGARITA, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality, identity verification, and address management solutions, today announced its support of healthcare practice management providers in meeting compliance with Project US@, a federal data initiative to create a unified, industrywide specification f
CHICAGO, August 18, 2023--Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K"), Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the "Q1 Form 10-Q") and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "Q2 Form